(:VRML)

Mar 23, 2022 07:00 am ET
Aspira Women’s Health Reports Fourth Quarter and Full Year 2021 Financial Results
Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the fourth quarter and year ended December 31, 2021. “We are pleased to...
May 05, 2021 08:00 am ET
Aspira Women’s Health Inc. to Report First Quarter 2021 Financial Results on May 13
Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that it will report financial results for the first quarter ended March 31, 2021 on Thursday, May 13, 2021, after the market close, followed by...
Sep 08, 2020 11:44 am ET
Aspira Women’s Health, Inc. to Present at Cantor Virtual Healthcare Conference
Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced management will participate in the 2020 Cantor Virtual Healthcare Conference taking place on September 15-17, 2020. Valerie Palmieri, President...
Aug 14, 2020 03:51 pm ET
UPDATE – Aspira Women’s Health Reports Second Quarter 2020 Financial Results
Aspira Women’s Health Inc. (“ASPIRA”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the second quarter ended June 30, 2020. “Despite late first quarter and...
Aug 13, 2020 04:01 pm ET
Aspira Women’s Health Reports Second Quarter 2020 Financial Results
Aspira Women’s Health Inc. (“ASPIRA”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the second quarter ended June 30, 2020. “Despite late first quarter and...
Jul 31, 2020 09:23 am ET
Aspira Women’s Health, Inc. to Report Second Quarter 2020 Financial Results on August 13th
Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced it will report financial results for the second quarter ended June 30, 2020 on Thursday, August 13, 2020 after the market close, followed by an...
Jul 01, 2020 11:23 am ET
Aspira Women’s Health Inc. Announces Equity Financing of Approximately $11 Million
Aspira Women’s Health Inc. (Nasdaq: AWH) (“ASPIRA”), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that investors, including certain affiliates of Jack W. Schuler, ASPIRA’s largest stockholder, have...
Jun 29, 2020 08:00 am ET
Aspira Women’s Health, Inc. Announces First Patient Enrolled in Prospective OVANex Study for Benign Pelvic Mass Monitoring
Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced the first patient enrolled in a national clinical study of benign pelvic mass management. The study will enroll over 1,000 women for assessing...
Jun 11, 2020 08:31 am ET
Vermillion, Inc. Announces Rebranding and Company Name Change to Aspira Women’s Health Inc.
Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on ovarian cancer risk assessment, today announced a major rebranding to reflect the company’s continuing evolution towards becoming a comprehensive gynecologic...
Jun 10, 2020 08:00 am ET
Vermillion Completes Validation of New Pre-Surgical Test Offerings with OVA1®plus, including COVID-19 Antibody Testing and Additional Pelvic Mass Risk Assessment Biomarkers
Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, is excited to announce that its wholly-owned subsidiary ASPIRA Labs has completed laboratory validation of the Roche Elecsys...
Jun 09, 2020 04:34 pm ET
Vermillion Set to Join Russell 3000® Index
Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2020 Russell indexes annual...
May 14, 2020 04:01 pm ET
Vermillion Reports First Quarter 2020 Financial Results
Vermillion, Inc. (Nasdaq: VRML), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the first quarter March 31, 2020. “Despite late first quarter challenges from COVID-19, we...
Apr 30, 2020 04:01 pm ET
Vermillion to Report First Quarter 2020 Financial Results on May 14
Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that it will report financial results for the first quarter ended March 31, 2020, on Thursday, May 14, 2020, after the...
Apr 14, 2020 08:00 am ET
Vermillion Inc. Announces ASPiRA LABS Now Credentialed as Florida State Medicaid Provider
Vermillion, Inc. (NASDAQ: VRML) today announced its wholly owned subsidiary, ASPiRA LABS, is now credentialed with Florida’s State Medicaid program for an estimated additional 3.6 million credentialed Medicaid lives. Florida has the fourth largest...
Mar 27, 2020 08:00 am ET
Vermillion Announces Cigna Preferred Contract Coverage for OVA1, Overa and Genetics Testing
Vermillion, Inc. (NASDAQ: VRML), a bioinformatics-based women’s health company focused on gynecologic disease, announced yesterday that its wholly owned subsidiary, ASPiRA Labs, has signed a national preferred agreement with Cigna. This contract...
Mar 26, 2020 04:01 pm ET
Vermillion Reports Fourth Quarter 2019 Financial Results
Vermillion, Inc. (Nasdaq: VRML), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the fourth quarter and year ended December 31, 2019. “We are very pleased with the overall...
Mar 04, 2020 08:00 am ET
Vermillion to Participate in Statewide “Women and Girls Day” at the Connecticut State Capital on March 6, 2020
Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced Valerie Palmieri will participate on a Women in Leadership Panel, representing the corporate sector, at “Women and Girls...
Mar 03, 2020 08:00 am ET
Vermillion to Report Fourth Quarter 2019 Financial Results on March 26
Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that it will report financial results for the fourth quarter and year ended December 31, 2019 on Thursday, March 26, 2020,...
Feb 25, 2020 04:01 pm ET
Vermillion to Participate at the 32nd Annual Roth Conference
Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that management will participate in the 32nd Annual Roth Conference taking place on March 15-17, 2020 in Laguna Niguel,...
Jan 09, 2020 04:05 pm ET
Chembio Diagnostics Announces CEO Transition
Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced President and Chief Executive Officer John Sperzel has resigned for another opportunity. The Chembio Board of...
Jan 02, 2020 04:05 pm ET
Vermillion to Present at 2020 Biotech Showcase; Participate in LifeSci Advisors Corporate Access Event
Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that management will participate in two investor events in San Francisco during the week of January 13, 2020. Vermillion...
Dec 17, 2019 08:00 am ET
Vermillion, Inc. and Einstein Medical Center Philadelphia Announce the First Patient Enrolled in Prospective National Clinical Study of Ovarian Cancer Risk Detection Methods in African American Women
Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease and Einstein Medical Center, the largest independent academic medical center in Philadelphia, today announced the first patient enrolled in a study that compares OVA1® to CA125 assay for detection of ovarian cancer risk in African American women.
Dec 03, 2019 06:00 am ET
GenomeSmartTM and ASPiRA LABS®, a Vermillion Company, Launch Pilot Program to Improve Access to Genetic Testing
GenomeSmart, a Silicon Valley-based company delivering the first and only AI-powered genetic risk assessment and test recommendation platform to improve access to genetic testing, today announced a pilot program with ASPiRA LABS®, a Vermillion company (Nasdaq: VRML), where GenomeBrainTM will be offered to a select group of providers to improve identification of patients who are at risk for hereditary cancer or passing hereditary diseases to their children.
Nov 21, 2019 08:00 am ET
Vermillion to Participate at the Piper Jaffray 31st Annual Healthcare Conference
Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that management will participate at the Piper Jaffray 31st Annual Healthcare Conference, taking place December 3-5, 2019...
Nov 12, 2019 04:05 pm ET
Vermillion Reports Third Quarter 2019 Financial Results
Vermillion, Inc. (Nasdaq: VRML), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the third quarter ended September 30, 2019. “We are very pleased by the continued positive...
Oct 08, 2019 04:15 pm ET
Vermillion to Report Third Quarter 2019 Financial Results on November 12
Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that it will report financial results for the three and nine months ended September 30, 2019 on Tuesday, November 12th,...
Sep 30, 2019 08:00 am ET
Vermillion to Participate at 2019 Cantor Global Healthcare Conference
Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that management will participate in one-on-one meetings at the 2019 Cantor Global Healthcare Conference, taking place...
Sep 04, 2019 08:00 am ET
Vermillion Announces Two Independent Publications Showing OVA1® (MIA- Multivariate Index Assay) Demonstrates Improved Ovarian Malignancy Risk Detection in African-American Women
Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced the publication of two independent studies demonstrating that OVA1® (Blood Multivariate Index Assay (MIA) for Ovarian Cancer Risk Assessment) improves ovarian cancer risk detection in women compared to alternative technology, such as CA125 and CA125 & HE4 (Risk of Malignancy Algorithm ROMA). With more than 80% of ovarian cancer being diagnosed in late stages1,2, these data support the National Ovarian Cancer Coalition’s mission for Ovarian C
Aug 08, 2019 04:05 pm ET
Vermillion Reports Second Quarter 2019 Financial Results
Vermillion, Inc. (Nasdaq: VRML), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the second quarter ended June 30, 2019. “We are very pleased by the continued positive momentum...
Jul 31, 2019 04:01 pm ET
Vermillion to Report Second Quarter 2019 Financial Results on August 8
Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that it will report financial results for the three and six months ended June 30, 2019 on Thursday, August 8, followed by...
Jul 16, 2019 08:00 am ET
Vermillion Announces Publication of New Study Demonstrating Overa’s Greater Sensitivity in Detecting Ovarian Cancer Compared with ROMA, HE4 + CA125, and CA125 Alone
Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced publication of a paper entitled: “Clinical Performance Comparison of Two In-Vitro Diagnostic Multivariate Index Assays (IVDMIAs) for Presurgical Assessment for Ovarian Cancer Risk” in the journal Advanced Therapeutics (
Jun 26, 2019 09:14 am ET
Vermillion, Inc. Announces Pricing of $15 Million Public Offering of Common Stock
Vermillion, Inc. (Nasdaq: VRML) (“Vermillion”), a bioanalytical-based women’s health company focused on gynecologic disease, today announced the pricing of the previously announced underwritten public offering of 18,750,000 shares of its common...
Jun 25, 2019 04:01 pm ET
Vermillion, Inc. Announces Proposed Public Offering of Common Stock
Vermillion, Inc. (Nasdaq: VRML) (“Vermillion”), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that it intends to offer shares of its common stock in an underwritten public offering. The offering is...
Jun 20, 2019 06:33 pm ET
Vermillion Adds Two Major Contracted Agreements for OVA1
Vermillion, Inc. (NASDAQ: VRML), a bioinformatics-based women’s health company focused on gynecologic disease, today announced it has further expanded preferred coverage of its OVA1 (Multivariate Index Assay, MIA) ovarian cancer risk assessment...
May 14, 2019 04:05 pm ET
Vermillion Reports First Quarter 2019 Financial Results
Vermillion, Inc. (NASDAQ: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today reported its financial results for the first quarter ended March 31, 2019. “We are very pleased by the reception of OVA1+, our...
May 13, 2019 04:01 pm ET
Vermillion Announces Acceptance of Publication Ethnic Disparity Data Showing OVA1® (MIA) Superiority over CA125 and HE4 in Detecting Ovarian Cancer Risk
Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced acceptance of a paper entitled: “Multivariate Index Assay is Superior to CA125 and HE4 Testing in Detection of Ovarian...
Apr 22, 2019 10:07 am ET
Vermillion to Report First Quarter 2019 Financial Results on May 14
Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that it will report financial results for the first quarter ended March 31, 2019 on Tuesday, May 14, followed by an...
Apr 17, 2019 07:10 am ET
Research Report Identifies Clearway Energy, BLACKROCK TCP CAPITAL CORP, Vermillion, Aspen Aerogels, P.A.M. Transportation Services, and Townsquare Media with Renewed Outlook — Fundamental Analysis, Ca
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clearway Energy, Inc. (NYSE:CWEN), BLACKROCK TCP CAPITAL CORP....
Apr 02, 2019 04:20 pm ET
Vermillion Exhibits OVA1 Ethnic Disparity Performance Poster at the American Association for Cancer Research (AACR) Annual Meeting
Vermillion, Inc. (NASDAQ: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, is being represented at the 2019 American Association for Cancer Research Annual Meeting with a poster entitled “Ethnic Disparity in...
Mar 28, 2019 04:01 pm ET
Vermillion Reports Fourth Quarter and Year-End 2018 Financial Results
Vermillion, Inc. (NASDAQ: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today reported its financial results for the fourth quarter and year ended December 31, 2018. “We are very pleased by the reception of...
Mar 12, 2019 12:27 pm ET
Vermillion to Report Fourth Quarter and Year End 2018 Financial Results on Thursday, March 28
Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that it will report financial results for the fourth quarter and year ended December 31, 2018 on Thursday, March 28,...
Jan 15, 2019 09:46 am ET
Vermillion Announces Coverage by Cigna for OVA1® (MIA)
Vermillion, Inc. (NASDAQ: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that Cigna has added OVA1® (MIA) to its national preferred coverage list effective January 15, 2019.  Cigna is one of the...
Nov 20, 2018 04:01 pm ET
Vermillion to Present at the Piper Jaffray 30th Annual Healthcare Conference
Vermillion, Inc. (Nasdaq: VRML), a bio-analytical-based women’s health company focused on gynecologic disease, today announced that Valerie Palmieri, President and CEO of Vermillion, will present at the upcoming Piper Jaffray 30th Annual Healthcare...
Nov 14, 2018 08:00 am ET
New Research Coverage Highlights Nexa Resources S.A, Qumu, Clearway Energy, Vermillion, Cantel Medical, and Theravance Biopharma — Consolidated Revenues, Company Growth, and Expectations for 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Nexa Resources S.A. (NYSE:NEXA), Qumu Corporation (NASDAQ:QUMU), Clearway...
Nov 12, 2018 08:00 am ET
Vermillion to Present at the Canaccord Medical Technology & Diagnostics Forum
Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President and Chief Executive Officer, and Robert Beechey, Chief Financial Officer, will present at the...
Nov 08, 2018 04:01 pm ET
Vermillion Announces OVA1® (MIA) and OVERA® (MIA2G) Study and Coverage by Clalit Health Services in Israel
Vermillion, Inc. (NASDAQ: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced a study agreement and coverage with Clalit Health Services in Israel. The study is intended to validate on the local...
Nov 08, 2018 04:01 pm ET
Vermillion Reports Third Quarter 2018 Financial Results
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today reported its financial results for the third quarter ended September 30, 2018. “We are pleased to report growth in revenues this quarter on...
Oct 26, 2018 04:05 pm ET
Vermillion to Report Third Quarter and Nine Months Ended September 30, 2018 Financial Results on Thursday, November 8
Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that it will report financial results for the third quarter and nine months ended September 30, 2018 on Thursday, November...
Oct 09, 2018 08:00 am ET
Vermillion, Inc. Announces the Launch of OVA1®+
Vermillion, Inc. (NASDAQ: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced the launch of its enhanced reflex offering OVA1®+, through its wholly owned subsidiary, ASPiRA Labs, Inc. The new...
Sep 06, 2018 09:00 am ET
Vermillion, Inc. Kicks Off Ovarian Cancer Awareness Month by Ringing the NASDAQ Closing Bell
Vermillion, Inc. (NASDAQ:VRML), a bioanalytical-based women’s health company focused on gynecologic disease, will ring the NASDAQ closing bell today.  “September is an opportunity for us to reach more women and raise awareness around ovarian...
Aug 21, 2018 04:01 pm ET
Vermillion, Inc. Appoints Nancy Cocozza to its Board of Directors
Vermillion, Inc. (NASDAQ: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced the appointment of Nancy G. Cocozza to its Board of Directors.  Ms. Cocozza joins the Board effective August 17, 2018, and...
Aug 09, 2018 04:01 pm ET
Vermillion Reports Second Quarter 2018 Financial Results
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today reported its financial results for the second quarter ended June 30, 2018. “We continue to make steady progress in our commercialization...
Jul 18, 2018 08:00 am ET
Vermillion to Report Second Quarter and Six Months Ended June 30, 2018 Financial Results on Thursday, August 9
Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that it will report financial results for the second quarter and six months ended June 30, 2018 on Thursday, August 9, followed by an...
Jun 13, 2018 11:08 am ET
Vermillion Names Chris Goulart to Senior Vice President of Commercial Operations
Vermillion, Inc. (NASDAQ:VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that Mr. Chris Goulart has been appointed as Senior Vice President of Commercial Operations, a newly created position focusing on the...
May 14, 2018 04:01 pm ET
Vermillion Reports First Quarter 2017 Financial Results
Vermillion, Inc. (NASDAQ:VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its financial results for the first quarter ended March 31, 2018. Valerie Palmieri, President and CEO, stated, “We commenced our...
May 03, 2018 04:01 pm ET
Vermillion to Report First Quarter 2018 Financial Results on Monday, May 14
Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its first quarter ended March 31, 2018 financial results on Monday, May 14, 2018, followed by an investor...
Apr 26, 2018 08:00 am ET
Vermillion Announces Recognition by and Publication in Two Top Physician Educational Resources
Article highlighting OVA1’s biomarker test published in the March 2018 issue of “UpToDate,” an evidence-based physician-authored publication
Apr 13, 2018 09:17 am ET
Vermillion, Inc. Announces Pricing of $15 Million Concurrent Public Offerings of Common Stock and Preferred Stock
AUSTIN, Texas, April 13, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, today announced the pricing of the previously announced concurrent but separate underwritten public offerings of 10,000,000 shares of its common...
Apr 12, 2018 04:44 pm ET
Vermillion, Inc. Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
AUSTIN, Texas, April 12, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that it intends to offer shares of its common stock and convertible preferred stock in concurrent but...
Mar 13, 2018 04:01 pm ET
Mar 07, 2018 04:01 pm ET
Vermillion to Present at the 30th Annual ROTH Conference
AUSTIN, Texas, March 07, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President and Chief Executive Officer, and Robert Beechey, Chief Financial Officer, are scheduled to...
Feb 28, 2018 08:00 am ET
Vermillion to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Tuesday, March 13
AUSTIN, Texas, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its fourth quarter and fiscal year ended December 31, 2017 financial results on...
Feb 23, 2018 08:00 am ET
Vermillion to Present at the 2018 BTIG Healthcare Conference
AUSTIN, Texas, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President and Chief Executive Officer, and Robert Beechey, Chief Financial Officer, are scheduled to...
Feb 05, 2018 07:45 am ET
Vermillion Announces the Grant of Two Ovarian Cancer Diagnostic Patents
AUSTIN, Texas, Feb. 5, 2018 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML) announced today that it has been granted two new US patents that significantly expand coverage for its core technologies, OVA1™ and Overa™.
Jan 18, 2018 07:45 am ET
Vermillion Announces Agreement with BlueCross BlueShield of Illinois
AUSTIN, Texas, Jan. 18, 2018 /PRNewswire/ -- ASPiRA Labs, a Vermillion company (NASDAQ: VRML) and exclusive distributor of OVA1 (Multivariate Index Assay, or MIA), an ovarian cancer risk assessment test, today announced it has entered into an agreement with BlueCross BlueShield of Illinois.
Dec 19, 2017 07:45 am ET
Vermillion Appoints Bob Beechey to Newly Created CFO Post
AUSTIN, Texas, Dec. 19, 2017 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced it has appointed Bob Beechey CPA to the newly created post of Chief Financial Officer.
Nov 21, 2017 07:45 am ET
Vermillion to Present at the 29th Annual Piper Jaffray Healthcare Conference
AUSTIN, Texas, Nov. 21, 2017 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President and Chief Executive Officer, will provide a corporate overview at the 29th Annual Piper Jaffray Healthcare Conference, being held at the Lotte New York Palace Hotel in New York City on November 28-29, 2017.
Nov 20, 2017 08:56 am ET
ASPiRA Labs Announces Release of Final CMS Reimbursement Rate for OVA1
AUSTIN, Texas, Nov. 20, 2017 /PRNewswire/ -- ASPiRA Labs, a Vermillion company (NASDAQ: VRML) and the exclusive distributor of OVA1 (Multivariate Index Assay) (MIA), and Overa (MIA2G), today announced that the Center for Medicare Services (CMS) has released the Final 2018 Clinical Lab Fee Schedule, effective January 1, 2018. 
Nov 16, 2017 08:45 am ET
Vermillion Announces Publication of Foundational Health Economics Study
AUSTIN, Texas, Nov. 16, 2017 /PRNewswire/ -- Vermillion (NASDAQ: VRML) announced today the acceptance and publication of a novel paper, "Economic Impact of Increased Utilization of Multivariate Assay Testing to Guide the Treatment of Ovarian Cancer: Implications for Payers" in the journal American Health and Drug Benefits.
Nov 08, 2017 04:01 pm ET
Vermillion Reports Third Quarter 2017 Results
AUSTIN, Texas, Nov. 8, 2017 /PRNewswire/-- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its financial results for the third quarter ended September 30, 2017.
Nov 06, 2017 03:30 pm ET
Vermillion to Present at the Canaccord Genuity 2017 Medical Technologies & Diagnostics Forum
AUSTIN, Texas, Nov. 6, 2017 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President and Chief Executive Officer, will provide a corporate overview at the Canaccord Genuity 2017 Medical Technologies & Diagnostics Forum, being held at the Westin Grand Central Hotel in New York City on November 9, 2017.
Nov 01, 2017 09:45 am ET
ASPiRA Labs Announces a Major Coverage Milestone - A 27% Increase in Covered Lives for OVA1
AUSTIN, Texas, Nov. 1, 2017 /PRNewswire/ -- ASPiRA Labs, a Vermillion company (NASDAQ: VRML) and the exclusive distributor of OVA1 (Multivariate Index Assay) (MIA), today announced that it has substantially expanded positive policy coverage with the addition of 14 key managed care providers. This positive coverage is a transition from negative policy to positive policy for many of these plans.
Oct 31, 2017 09:45 am ET
ASPiRA Labs Announces OVA1 Contract with Louisiana Blue Cross Blue Shield
AUSTIN, Texas, Oct. 31, 2017 /PRNewswire/ -- ASPiRA Labs, a Vermillion company (NASDAQ: VRML) and exclusive distributor of OVA1 (Multivariate Index Assay, or MIA), an ovarian cancer risk assessment test, today announced it has entered into an agreement with Blue Cross Blue Shield of Louisiana.
Oct 27, 2017 09:45 am ET
ASPiRA Labs Lands Strategic Managed Care Coverage and Medicaid Licensure for OVA1®
AUSTIN, Texas, Oct. 27, 2017 /PRNewswire/ -- ASPiRA Labs, a Vermillion company (NASDAQ: VRML), today announced it has entered into agreements with Joint Venture Hospital Laboratories, LLC ("JVHL"), QCA Health Plan of Arkansas, Inc.  (d/b/a Qualchoice), Louisiana State Medicaid program, and Arizona State Medicaid Program to provide coverage for its in vitro diagnostic test, OVA1®.
Oct 25, 2017 05:01 pm ET
Vermillion to Report Third Quarter 2017 Financial Results and Host Investor Conference Call on November 8th
AUSTIN, Texas, Oct. 25, 2017 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its third quarter 2017 financial results on Wednesday, November 8, 2017, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.
Oct 02, 2017 05:45 pm ET
ASPiRA Labs Announces In-Network Contract Agreement with HealthNet Federal Services for OVA1®
AUSTIN, Texas, Oct. 2, 2017 /PRNewswire/ -- ASPiRA Labs, a Vermillion company (NASDAQ: VRML), today announced it has entered into an in-network contract agreement with HealthNet Federal Services, effective January 1, 2018.  This contract brings total TriCare coverage for ASPiRA Labs to over 9.4 million lives.
Aug 31, 2017 03:00 pm ET
Vermillion and ASPiRA Labs Kick Off Ovarian Cancer Awareness Month with 100,000th Patient Test Milestone and Ringing the Nasdaq Opening Bell
AUSTIN, Texas, Aug. 31, 2017 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML) will launch Ovarian Cancer Awareness Month by ringing the opening bell on Friday, September 1, joined by the New York City chapter of the National Ovarian Cancer Coalition. In the U.S. this year, there is estimated to be approximately 22,000 cases of ovarian cancer and more than 14,000 deaths resulting from this disease.
Aug 09, 2017 05:01 pm ET
Vermillion Reports Second Quarter 2017 Results
AUSTIN, Texas, Aug. 9, 2017 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its financial results for the second quarter ended June 30, 2017.
Aug 04, 2017 01:45 pm ET
Vermillion Announces Date Change of Second Quarter 2017 Financial Results and Investor Conference Call
AUSTIN, Texas, Aug. 4, 2017 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will now report its second quarter 2017 financial results on Wednesday, August 9, 2017, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.
Aug 01, 2017 05:01 pm ET
Vermillion to Present at the Canaccord Genuity 37th Annual Growth Conference on August 10th
AUSTIN, Texas, Aug. 1, 2017 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that Valerie Palmieri, President and Chief Executive Officer, will provide a corporate overview at the Canaccord Genuity 37th Annual Growth Conference, being held August 9-10 in Boston, Massachusetts.
Jul 27, 2017 05:01 pm ET
Vermillion to Report Second Quarter 2017 Financial Results and Host Investor Conference Call on August 8th
AUSTIN, Texas, July 27, 2017 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its second quarter 2017 financial results on Tuesday, August 8, 2017, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.
May 11, 2017 09:00 am ET
Vermillion Reports First Quarter 2017 Results
AUSTIN, Texas, May 11, 2017 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its financial results for the first quarter ended March 31, 2017.
Apr 26, 2017 05:00 pm ET
Vermillion to Report First Quarter 2017 Financial Results and Host Investor Conference Call on May 11
AUSTIN, Texas, April 26, 2017 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its first quarter 2017 financial results on Thursday, May 11, 2017, followed by an investor conference call and webcast at 8:30 a.m. Eastern Time.
Mar 30, 2017 09:00 am ET
ASPiRA Labs Announces TriCare South Contract
AUSTIN, Texas, March 30, 2017 /PRNewswire/ -- ASPiRA Labs, a Vermillion company (NASDAQ: VRML), today announced it has signed an in-network, contracted agreement with TriCare South for ASPiRA's U.S. FDA cleared, Centers for Medicare and Medicaid Services (CMS) covered, American College of Obstetricians and Gynecologists (ACOG) Level B recommended ovarian cancer risk assessment test, OVA1® (Multivariate Index Assay or MIA). TriCare South serves about 2.5 million beneficiaries in the states of Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, Oklahoma, South Carolina, Tennessee, Tex
Mar 29, 2017 05:01 pm ET
Vermillion Reports Fourth Quarter and Full Year 2016 Results
AUSTIN, Texas, March 29, 2017 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its results for the fourth quarter and full year ended December 31, 2016.
Mar 29, 2017 09:00 am ET
Vermillion Announces Publication of Ovarian Cancer Symptoms Index Study
AUSTIN, Texas, March 29, 2017 /PRNewswire/ -- Vermillion (NASDAQ: VRML) announced today the acceptance for publication of the original research titled, "Evaluation of a Validated Biomarker Test in Combination With a Symptom Index to Predict Ovarian Malignancy," by Renata R. Urban, MD, Alan Smith, MS, Kathy Agnew, Vinicius Bonato, PhD, and Barbara A. Goff, MD, in the International Journal of Gynecological Cancer.
Mar 15, 2017 04:00 pm ET
Vermillion to Report Fourth Quarter and Full Year 2016 Financial Results and Host Investor Conference Call on March 29, 2017
AUSTIN, Texas, March 15, 2017 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its fourth quarter and full year 2016 financial results on Wednesday, March 29, 2017, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.
Mar 06, 2017 04:05 pm ET
ASPiRA LABs Announces Provider Status with Medi-Cal Expanding OVA1® Access to Over 12 Million Beneficiaries
AUSTIN, Texas, March 6, 2017 /PRNewswire/ -- ASPiRA LABs, a Vermillion company (NASDAQ: VRML), today announced it has attained out-of-state provider status with Medi-Cal, California's Medicaid program, for OVA1®/Multivariate Index Assay (MIA). ASPiRA Labs is the sole source provider for OVA1 (MIA), an FDA cleared, ACOG recommended1 ovarian cancer risk assessment test. With ASPiRA Labs' out-of-state provider status with Medi-Cal, OVA1 (MIA) is now available to over 12 million Medi-Cal beneficiaries, representing approximately a third of the covered lives in California.
Mar 01, 2017 04:05 pm ET
ASPiRA LABs Announces Contracted In-Network Agreement with Blue Cross Blue Shield of Michigan for OVA1®
AUSTIN, Texas, March 1, 2017 /PRNewswire/ -- ASPiRA LABs, a Vermillion company (NASDAQ: VRML), today announced a major contracted agreement with Blue Cross Blue Shield of Michigan for ASPiRA's U.S. FDA cleared, American College of Obstetricians and Gynecologists (ACOG) recommended ovarian cancer risk assessment test, OVA1 (MIA). Blue Cross Blue Shield of Michigan serves over six million beneficiaries throughout Michigan and surrounding states.
Feb 14, 2017 08:30 am ET
Vermillion Announces Equity Financing of $5.6 Million
AUSTIN, Texas, Feb. 14, 2017 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company, announced today that investors, including several Vermillion directors and members of management as well as certain significant stockholders, have agreed to purchase approximately $5.6 million of unregistered shares of Vermillion's common stock and warrants to purchase unregistered shares of Vermillion's common stock in a private placement. Under the terms of the private placement, Vermillion has agreed to sell an aggregate of 3,747,125 shares of its common stock at the price of
Jan 04, 2017 04:05 pm ET
Vermillion and ASPiRA LABS Announce Receipt of Formal FDA Clarification Regarding Ovarian Cancer Screening Alert
AUSTIN, Texas, Jan. 4, 2017 /PRNewswire/ -- Vermillion (NASDAQ: VRML) and ASPiRA LABS, a Vermillion company, today announced the receipt of an FDA Clarification Letter regarding OVA1 (MIA) and Overa (MIA2G).  This letter (see attached) is in reference to the September 7, 2016 FDA Safety Communication advising women and their physicians against the use of ovarian cancer screening tests for asymptomatic women.
Nov 14, 2016 04:05 pm ET
Vermillion Announces Appointment of Chief Medical Officer
AUSTIN, Texas, Nov. 14, 2016 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company today announced that Marra Francis, MD has been appointed to the position of Chief Medical Officer as of November 8th.
Nov 14, 2016 09:00 am ET
Vermillion to Present Corporate Overview at the Canaccord Genuity Medical Technology and Diagnostic Forum
AUSTIN, Texas, Nov. 14, 2016 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President and Chief Executive Officer of Vermillion, Inc., will present a corporate overview at the Canaccord Genuity Medical Technology and Diagnostics Forum Conference.
Nov 10, 2016 04:03 pm ET
Vermillion Reports Third Quarter 2016 Results
AUSTIN, Texas, Nov. 10, 2016 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported its financial results for the third quarter ended September 30, 2016.
Nov 09, 2016 04:05 pm ET
ASPiRA LABS' OVA1 Technology Receives "Level B" Recommendation in the Latest ACOG Clinical Management Guidelines for the Management of Adnexal Masses
AUSTIN, Texas, Nov. 9, 2016 /PRNewswire/ -- ASPiRA LABS, a Vermillion company (NASDAQ: VRML), today announced the inclusion of the OVA1 /"Multivariate Index Assay" in The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin Number 174, dated November 2016. This bulletin outlines ACOG's "new" clinical management guidelines for adnexal mass management.  
Oct 27, 2016 10:00 am ET
Vermillion to Report Third Quarter 2016 Financial Results and Host Investor Conference Call on November 10th
AUSTIN, Texas, Oct. 27, 2016 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its third quarter financial results on Thursday, November 10, 2016, followed by an investor conference call and webcast at 4:30 p.m. (ET).
Oct 19, 2016 10:00 am ET
Vermillion CEO to Present at Women in Bio - New York
AUSTIN, Texas, Oct. 19, 2016 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that CEO, Valerie Palmieri, will present at the Women in Bio - New York Chapter meeting at the PRIDE Global Event Space in New York, NY on October 20, 2016 at 6:00PM EST.  The presentation, titled "Ovarian Cancer: Changing the Early Detection Paradigm and Controlling Your Destiny" will describe the who, what, why and how of the country's most deadly gynecologic malignancy.  The discussion will include a review of the disease symptoms
Sep 29, 2016 10:00 am ET
ASPiRA LABs OVA1® Test Now Covered By CareFirst BlueCross BlueShield
AUSTIN, Texas, Sept. 29, 2016 /PRNewswire/ -- ASPiRA LABs, a Vermillion company (NASDAQ: VRML), today announced a major contract agreement with CareFirst BlueCross BlueShield for their U.S. FDA cleared ovarian cancer risk assessment test, OVA1. CareFirst serves over three million patients throughout Maryland and Washington, D.C., and Virginia and the area has the greatest population density in the US.
Sep 09, 2016 08:30 am ET
Vermillion and ASPiRA LABs Applaud the FDA's Position on Ovarian Cancer Screening
AUSTIN, Texas, Sept. 9, 2016 /PRNewswire/ -- ASPiRA LABs, a Vermillion company (NASDAQ:VRML), today announced its support for the recent US Food and Drug Administration (FDA) safety communication which recommends against the use of any screening tests for ovarian cancer.
Sep 07, 2016 10:00 am ET
ASPiRA LABs Partners with New York Yankees Manager Joe Girardi for Ovarian Cancer Awareness Campaign Promoting Earlier Diagnosis
AUSTIN, Texas, Sept. 7, 2016 /PRNewswire/ -- ASPiRA LABs, a Vermillion company (NASDAQ: VRML), is proud to be partnering with New York Yankees Manager, Joe Girardi, in its latest national campaign, "Everyone Knows Someone," which, in support of Ovarian Cancer Awareness Month, aims to highlight that "everyone" is impacted by ovarian cancer.  
Sep 01, 2016 04:14 pm ET
Vermillion, Inc. Kicks Off Ovarian Cancer Awareness Month by Ringing the NASDAQ Closing Bell with Olympic Gymnast Shannon Miller, and NASCAR Driver Martin Truex, Jr.'s Life Partner, Sherry Pollex
AUSTIN, Texas, Sept. 1, 2016 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, brings its ASPiRA LABs' OVA1® awareness team members, Olympic Gold Medal Gymnast Shannon Miller and the life partner of NASCAR Driver Martin Truex, Jr., Sherry Pollex, to ring the NASDAQ Closing Bell today.  Both women are ovarian cancer survivors and join Vermillion at NASDAQ to launch September, Ovarian Cancer Awareness Month.
Aug 31, 2016 10:00 am ET
Aug 10, 2016 08:30 am ET
Vermillion Reports Second Quarter 2016 Results
AUSTIN, Texas, Aug. 10, 2016 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported its financial results for the second quarter ended June 30, 2016.
Aug 08, 2016 10:00 am ET
Vermillion to Present Corporate Overview at the Canaccord Genuity 36th Annual Growth Conference
AUSTIN, Texas, Aug. 8, 2016 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President and Chief Executive Officer of Vermillion, Inc., will present a corporate overview at the Canaccord Genuity 36th Annual Growth Conference.
Aug 02, 2016 05:05 pm ET
ASPiRA LABS Expands Coverage for OVA1® in California
AUSTIN, Texas, Aug. 2, 2016 /PRNewswire/ -- ASPiRA LABS, a Vermillion company (NASDAQ: VRML), today announced an agreement has been reached with Sacramento-based Sutter Valley Medical Foundation (d/b/a Gould Medical Foundation) for coverage of OVA1, Vermillion's ovarian cancer risk assessment test commercialized by ASPiRA LABS. 
Jul 29, 2016 10:00 am ET
Vermillion to Report Second Quarter 2016 Financial Results and Host Investor Conference Call on August 10th
AUSTIN, Texas, July 29, 2016 /PRNewswire/ -- Vermillion, Inc. (VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its second quarter financial results on Wednesday, August 10, 2016, followed by an investor conference call and webcast at 8:00 a.m. (ET).
Jul 27, 2016 10:00 am ET
ASPiRA LABS Expands Coverage for OVA1 in Texas
AUSTIN, Texas, July 27, 2016 /PRNewswire/ -- ASPiRA LABS, a Vermillion company (NASDAQ: VRML), today announced an agreement with Independent Medical Systems, a preferred provider organization (PPO) based in Dallas, Texas for coverage of ASPiRA LABS' ovarian cancer risk assessment test, OVA1.
Jul 19, 2016 10:15 am ET
ASPiRA LABS Announces Strategic Michigan Coverage for OVA1
AUSTIN, Texas, July 19, 2016 /PRNewswire/ -- ASPiRA LABS, a Vermillion company (NASDAQ: VRML), today announced an agreement with Priority Health Managed Benefits, a Michigan healthcare insurance company, for coverage of ASPiRA LABS' ovarian cancer risk assessment test, OVA1.
May 16, 2016 05:01 pm ET
Vermillion Reports First Quarter 2016 Results
AUSTIN, Texas, May 16, 2016 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its financial results for the first quarter ended March 31, 2016.
May 16, 2016 10:00 am ET
Vermillion to Showcase Comparison of Overa™ and ROMA™ Algorithms at ACOG 2016 Annual Meeting
AUSTIN, Texas, May 16, 2016 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company today announced positive top line results from a study entitled, "Clinical Performance Comparison of Two IVDMIAs for Pre-Surgical Assessment of Ovarian Cancer Risk", presented at the annual meeting of American Congress of Obstetricians and Gynecologists (ACOG), taking place May 14th thru May 17th in Washington DC.  Overa™ is Vermillion's FDA-cleared second-generation version of the OVA1 blood test, used for pre-surgical assessment of ovarian cancer risk in women undergoing surgery
May 02, 2016 05:05 pm ET
Vermillion to Report First Quarter 2016 Financial Results and Host Investor Conference Call on May 16
AUSTIN, Texas, May 2, 2016 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its first quarter 2016 financial results on Monday, May 16, 2016, followed by an investor conference call and webcast at 4:30pm Eastern.
Mar 24, 2016 09:00 am ET
Vermillion Reports Fourth Quarter and Full Year 2015 Results
AUSTIN, Texas, March 24, 2016 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its results for the fourth quarter and full year ended December 31, 2015.
Mar 21, 2016 10:30 am ET
Vermillion Announces Date Change for Fourth Quarter and Full Year 2015 Financial Results
AUSTIN, Texas, March 21, 2016 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today it will report its fourth quarter and full year 2015 financial results on Thursday, March 24, 2016, followed by an investor conference call and webcast at 8:30am Eastern.
Mar 21, 2016 09:15 am ET
Vermillion Announces FDA Clearance of Overa®, Second Generation OVA1® Test
AUSTIN, Texas, March 21, 2016 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today the receipt of 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) for the successor to Vermillion's OVA1® test for determining ovarian cancer risk in conjunction with independent clinical and imaging assessment prior to planned surgery for a women with a pelvic mass. The Second Generation OVA1 test, previously referred to as "OVA2", has been trademarked "Overa®." 
Mar 15, 2016 10:00 am ET
Vermillion to Report Fourth Quarter and Full Year 2015 Financial Results and Host Investor Conference Call on March 30
AUSTIN, Texas, March 15, 2016 /PRNewswire/ -- Vermillion, Inc. (VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its fourth quarter and full year 2015 financial results on Wednesday, March 30, 2016, followed by an investor conference call and webcast at 8:30am Eastern.
Mar 11, 2016 11:00 am ET
National Academy of Medicine Ovarian Cancer Report Ignites Reaction from Vermillion & OVA1® Awareness Team
AUSTIN, Texas, March 11, 2016 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, responded to the National Academy of Medicine (NAM) March report on ovarian cancer by launching a first of its kind pelvic mass website www.KnowPelvicMass.com along with a national advertising campaign debuting in USA TODAY on March 11th which spotlights pelvic mass. 
Feb 16, 2016 09:00 am ET
Vermillion Teams up With NASCAR Driver Martin Truex, Jr. and Partner Sherry Pollex, an Ovarian Cancer Thriver, to "Accelerate" the National Conversation about Ovarian Cancer and OVA1®
AUSTIN, Texas, Feb. 16, 2016 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that NASCAR Sprint Cup Driver Martin Truex, Jr. and his longtime partner, Sherry Pollex, an ovarian cancer thriver, will be in the driver seats for the new OVA1® Awareness Team. Vermillion's OVA1® Awareness Team will ignite an ongoing dialogue about pelvic masses, the signs and symptoms of ovarian cancer, along with use of the OVA1® blood test. OVA1® is the first FDA-cleared blood test to evaluate the ovarian cancer risk of a pelvic
Feb 11, 2016 09:00 am ET
Vermillion's CPRIT-Sponsored Pelvic Mass Registry Steering Committee Chartered
AUSTIN, Texas, Feb. 11, 2016 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced the formation of the Steering Committee for its Pelvic Mass Registry.
Feb 09, 2016 09:00 am ET
Vermillion Lands America's Most Decorated Gymnast and Ovarian Cancer Survivor, Shannon Miller, for its OVA1® Awareness Team
AUSTIN, Texas, Feb. 9, 2016 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced the most decorated gymnast in American history has joined its new OVA1 Awareness Team. As a member of Vermillion's Awareness Team, Shannon Miller will be tasked with "spring boarding" an ongoing dialogue about pelvic masses, the signs and symptoms of ovarian cancer, along with the use of the OVA1 blood test.  OVA1 is the first FDA-cleared blood test used to evaluate the cancer risk of a pelvic mass. Shannon is an ovarian cancer surviv
Jan 19, 2016 09:00 am ET
Vermillion to Present at 7th Annual Life Science CEO Forum
AUSTIN, Texas, Jan. 19, 2016 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that it will present at the 7th Annual Life Science CEO Forum on January 25-26 in Atlanta GA at the Westin Buckhead Hotel. Valerie Palmieri, President and Chief Executive Officer of Vermillion, will present on "The Plight of Ovarian Cancer, a Pelvic Mass Care Pathway Solution and Getting Paid," highlighting the use of Vermillion's OVA1® diagnostic test, at 5:00 PM EST on January 25th. Ms. Palmieri will be joined in the conference by

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.